Firefly Neuroscience

AIFF · NASDAQ

$1.06+$0.06 (+6.00%)TodayMarket closed ·
Prev close $1.00

About AIFF

Firefly Neuroscience, Inc. is an artificial intelligence (AI) technology company, which engages in developing neuroscientific solutions for mental illnesses and neurological disorders. The company is headquartered in Kenmore, New York and currently employs 17 full-time employees. The firm's BNA Platform and Evoke System are Class II medical devices, which were cleared by FDA for commercialization. The firm's FDA-510(k) cleared Evoke System, commercially deployed as the Evoke System, is in active use over 85 clinical sites in the United States. The firm has developed Firefly Platform, a vertically integrated hardware, software, and data infrastructure that captures standardized electroencephalographic (EEG) and event-related potential (ERP) assessments at the point of care, analyzes that data through its proprietary analytics engine, and delivers structured, clinician-ready reports back to the provider, all within a single seamless workflow. Its proprietary analytics engine analyzes raw EEG and ERP signals across captured dimensions and compares each patient’s electrophysiological profile to a reference dataset.

Employees
17
Headquarters
Kenmore, New York
Listed
Oct 27, 1993
Sector
Health Care
Industry
Health Care Technology

AIFF key statistics

Market cap
16.63M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
7.49M
Volume
52.13K
Open price
$1.01
High today
$1.08
Low today
$1.01
52 Week high
$3.15
52 Week low
$0.6175

Firefly Neuroscience (AIFF) at a glance

As of Oct 20, 2026, Firefly Neuroscience (AIFF) shares are priced at $1.06, giving the company a market cap of 16.63M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.01 and $1.08. The current price is 5.0% above the day's low and 1.9% below its high.

Volume so far is 52.13K shares, below the average of 7.49M shares a day.

Over the past year Firefly Neuroscience has ranged from $0.6175 to $3.15, and now sits 17% of the way up that range.

Firefly Neuroscience met or beat analyst EPS estimates in 0 of the last 2 quarters. In Q3 FY98 it reported -$12.90 per share against an estimate of $3.37.

AIFF earnings

Earnings per share, reported against the analyst estimate

Didn’t beat the estimate in any of the last 2 quarters.

  1. Q2 FY98: reported $1.20 per share against an estimate of $1.84
  2. Q3 FY98: reported -$12.90 per share against an estimate of $3.37

AIFF news

  • Avi Kapoor

    Gold Fields, Harmony Gold Mining, Anglogold Ashanti And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

  • Avi Kapoor

    Why Webuy Global Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

  • Vandana Singh

    Firefly Neuroscience and Neurosigma Partner To Expand Non-Drug Pediatric ADHD Care

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • Vandana Singh

    What's Going On With Firefly Neuroscience Stock On Friday?

  • 12 Health Care Stocks Moving In Friday's Intraday Session

Similar companies

Companies in the same industry as Firefly Neuroscience

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.